Drug Profile
Molgramostim biosimilar - Amega Biotech
Alternative Names: recombinant GM-CSF - Amega BiotechLatest Information Update: 15 Aug 2013
Price :
$50
*
At a glance
- Originator Amega Biotech
- Class Antibacterials; Antibronchitics; Antifibrotics; Antineoplastics; Chemoprotectants; Immunotherapies; Recombinant proteins
- Mechanism of Action Granulocyte macrophage colony stimulating factor agonists; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase Unknown Leucopenia; Neutropenia
Most Recent Events
- 15 Aug 2013 Investigation in Leucopenia in Argentina (Parenteral)
- 15 Aug 2013 Investigation in Neutropenia in Argentina (Parenteral)